ESC 365 - SGLT2 inhibition: the potential to change the heart failure landscape?

Open Access

SGLT2 inhibition: the potential to change the heart failure landscape?

Session: Heart failure: what is the potential of SGLT2 inhibition?

Topic: Chronic Ischaemic heart disease

Speaker: Doctor M. Kosiborod (Kansas City, US)

Sponsored by AstraZeneca

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Congress Presentation

Add to my library

About the speaker

Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)

55 presentations

9 followers

5 more presentations in this session

Welcome and introduction.

Speaker: Doctor S. Williams (Manchester, GB) Doctor J. Day (Luton, GB)

The ongoing problem of heart failure.

Speaker: Professor J. McMurray (Glasgow, GB)

The ongoing problem of heart failure - Q&A.

Speaker: Professor J. McMurray (Glasgow, GB) Doctor S. Williams (Manchester, GB)

SGLT2 inhibition: the potential to change the heart failure landscape? Q&A.

Summary and close.

Speaker: Doctor S. Williams (Manchester, GB)

Access the full session

Heart failure: what is the potential of SGLT2 inhibition?

Speakers: Doctor M. Kosiborod, Doctor S. Williams, Doctor J. Day, Professor J. McMurray, Professor J. McMurray...

About the event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources